Detection of SARS-CoV-2 RNA by direct RT-qPCR on nasopharyngeal specimens without extraction of viral RNA

Mohammad Rubayet Hasan[1,2], Faheem Mirza[1], Hamad Al-Hail[1], Sathyavathi Sundararaju[1], Thabisile Xaba[1], Muhammad Iqbal[1], Hashim Alhussain[3], Hadi Mohamad Yassine[3], Andres Perez Lopez[1,2], Patrick Tang[1,2]

[1]Department of Pathology, Sidra Medicine; [2]Weill Cornell Medical College in Qatar, Doha, Qatar; [3]Qatar University, Doha, Qatar

Short title: SARS-CoV-2 detection by RT-qPCR without RNA extraction

Corresponding author:

Mohammad Rubayet Hasan, PhD, FCCM, D(ABMM)

Clinical Molecular Microbiologist, Department of Pathology

Assistant Professor of Clinical Pathology and Laboratory Medicine

Weill Cornell Medical College in Qatar (WCMC-Q)

Sidra Medicine

Office no: H2M-24093

PO Box 26999, Doha, Qatar

Direct: +974 4003 2996

Mobile: +974 3003 5501

mhasan@sidra.org / http://www.sidra.org/doctors/mohammad-rubayet-hasan/

Abstract

To circumvent the limited availability of RNA extraction reagents, we aimed to develop a protocol for direct RT-qPCR to detect SARS-CoV-2 in nasopharyngeal swabs without RNA extraction. Nasopharyngeal specimens positive for SARS-CoV-2 and other coronaviruses collected in universal viral transport (UVT) medium were pre-processed by several commercial and laboratory-developed methods and tested by RT-qPCR assays without RNA extraction using different RT-qPCR master mixes. The results were compared to that of standard approach that involves RNA extraction. Incubation of specimens at 65ºC for 10 minutes along with the use of TaqPath™ 1-Step RT-qPCR Master Mix provides higher analytical sensitivity for detection of SARS-CoV-2 RNA than many other conditions tested. The optimized direct RT-qPCR approach demonstrated a limit of detection of 6.6×10^3 copy/ml and high reproducibility (co-efficient of variation = 1.2%). In 132 nasopharyngeal specimens submitted for SARS-CoV-2 testing, the sensitivity, specificity and accuracy of our optimized approach were 95%, 99% and 98.5%, respectively, with reference to the standard approach. Also, the RT-qPCR C_T values obtained by the two methods were positively correlated (Pearson correlation coefficient r=0.6971, p=0.0013). The rate of PCR inhibition by the direct approach was 8% compared to 9% by the standard approach. Our simple approach to detect SARS-CoV-2 RNA by direct RT-qPCR may help laboratories continue testing for the virus despite reagent shortages or expand their testing capacity in resource limited settings.

Introduction

The ongoing pandemic of coronavirus disease (COVID-19) caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) posed an unprecedented public health threat to the entire world. In the absence of an effective vaccine or specific treatment against the virus, early detection and contact tracing, physical distancing measures and quarantine of cases are considered the cornerstones to curb the community transmission of SARS-CoV-2 [1-3]. Since the virus was identified and its genome sequenced in early January 2020, detection of viral RNA in respiratory specimens by real-time reverse transcription PCR (RT-qPCR) remains the main approach to manage the outbreak by allowing early detection of cases and targeted measures to prevent transmission of the virus [4]. The massive demand for SARS-CoV-2 RT-qPCR has brought about a global shortage and supply chain irregularities of RNA extraction kits that are crucial for RT-qPCR testing [5-7]. In this study, we tested a number of commercial and laboratory-developed, specimen pre-treatment procedures to optimize the performance of direct RT-qPCR for SARS-CoV-2 avoiding the RNA extraction step. This method was validated against a standard approach that included extraction of viral RNA on a commercial automated extraction platform.

Materials and methods

Standard approach for detection of SARS-CoV-2 RNA from nasopharyngeal specimens in our laboratory involves extraction of total nucleic acids from specimens in an IVD-labeled, automated extraction platform followed by RT-qPCR, based on one of the assays (Table 1) suggested by World Health Organization (WHO)[8]. The performance standards of the assay were established in our laboratory according to College of American Pathologists (CAP)

69 standards, and at time of writing this paper, the assay was used to test more than 2000 respiratory
70 specimens to screen patients for potential infection with SARS-CoV-2. Therefore, the assay was
71 used as the reference method for all other alternative approaches assessed in this study. All
72 specimen preparations, pre-treatments and PCR setup were performed in a Class II Biosafety
73 cabinet in a Biosafety level 2 (BSL2) facility.

74 Clinical specimens: Nasopharyngeal flocked swab (NPFS) specimens collected in
75 universal viral transport (UVT) medium (Becton, Dickinson and Company) (n= 150) submitted
76 for testing SARS-CoV-2 or other respiratory viruses at Sidra Medicine, Doha, Qatar were used in
77 this study. To maintain patient anonymity, each sample was coded, and all patient identifiers
78 were removed to ensure that personnel involved in this study were unaware of any patient
79 information. Ethics approval was not sought because the study involves laboratory validation of
80 test methods and the secondary use of anonymous pathological specimens that falls under the
81 category 'exempted' by Sidra Medicine Institutional Review Board. For spiking experiments,
82 NPFS specimens (n=6) were collected from laboratory volunteers after obtaining written
83 informed consents. No personal data were collected, and specimens were labeled with random
84 numbers so that test results cannot be linked to an individual.

85 Nucleic acid extraction: Nucleic acids from 0.2 ml of NPFS specimens were extracted on
86 a NucliSENS® easyMAG platform (bioMérieux, France) according to the methods described by
87 the manufacturers.

88 Pre-treatment of specimens: Unless otherwise stated, specimens were diluted using
89 nuclease free water. Heat treatment of specimens at different temperature was performed in a
90 ThermoMixer (Eppendorf). Specimens processed with Arcis Coronavirus RNA extraction
91 research kit (Arcis Biotechnology) were performed according to manufacturer's instructions.

92 Briefly, 90 µl specimen was mixed with 6 µl Reagent 1 RTU and either left unheated or heat
93 lysed at 60°C for 5 minutes. 40 µl of lysate was then mixed with 2 µl of Reagent 2a and was used
94 directly for Rt-qPCR. For Takara PrimeDirect™ Probe RT-qPCR Mix (Takara Bio), 0.2 ml
95 specimens were heated at 99°C for 10 mins and then centrifuged at 4000rpm for 5 min. The
96 supernatants were collected and 7µl of supernatant was directly used in RT-qPCR reaction
97 mixture.

98 RT-qPCR: Primers and probes for detection of SARS-CoV-2, HCoV-HKU1 and MS2
99 bacteriophage are listed in Table S1 [4,9,10]. For detection of HCoV-HKU1 using Quantifast
100 Pathogen RT-PCR + IC kit (Qiagen), five µl of extracted or pre-treated samples were mixed with
101 20 µl of a master mix containing 5 µl of Quantifast Pathogen RT-PCR + IC Master Mix, 0.25 µl
102 of Quantfast RT Mix and 0.5 µl of 50 x ROX dye solution and primers and probes to final
103 concentrations shown in Table S1. Thermal cycling was performed in a ABI7500 Fast instrument
104 (Thermofisher Scientific) with 1 cycle of reverse transcription at 50°C for 20 min followed by 1
105 cycle of PCR activation at 95°C for 5 min, followed by 40 amplification cycles each consisting
106 of 95°C-15s and 60°C-60s. For detection of HCoV-HKU1 using TaqPath™ 1-Step RT-qPCR kit
107 (Thermofisher Scientific), five µl of extracted or pre-treated samples were mixed with 5 µl of a
108 master mix containing 5 µl of TaqPath™ 1-Step RT-qPCR Master Mix and primers and probes
109 to final concentrations shown in Table S1. Thermal cycling was performed in a ABI7500 Fast
110 instrument (Thermofisher Scientific) with 1 cycle of reverse transcription at 50°C for 15 min
111 followed by 1 cycle of polymerase activation at 95°C for 2 min, followed by 40 amplification
112 cycles each consisting of 95°C-15s and 60°C-60s.

113 For detection of SARS-CoV-2 with standard method, five µl of nucleic acid extracts from
114 NucliSENS® easyMAG system were mixed with 7.5 µl of a master mix containing 2.5 µl of

115 Quantifast Pathogen RT-PCR + IC Master Mix, 0.125 µl of Quantfast RT Mix and 0.25 µl of 50
116 X ROX dye solution and primers and probes to final concentrations shown in Table S1. RNA
117 extraction and PCR inhibition were monitored by an internal control PCR assay, using the
118 primers and probes shown in Table S1. Specimens were spiked with a tittered preparation of
119 MS2 bacteriophage to serve as a template for internal control assay. For direct PCR on
120 specimens, pre-treated specimens were assessed in the same way except that extracted MS2
121 bacteriophage RNA was mixed with PCR master mix to serve as an inhibition control. A
122 synthetic RNA (IDT) based on E-Sarbeco assay [4] amplicon sequence was used as a positive
123 control. As negative control, 0.2 ml neonatal calf serum (NCS) (Thermofisher Scientific) was
124 extracted along with specimens and used with each PCR run. SARS-CoV-2 RT-qPCR with
125 Takara PrimeDirect™ Probe RT-qPCR Mix was performed as described by the manufacturer.
126 Briefly, 7 µl of processed samples were mixed with 18 µl of master mix containing 12.5 µl of
127 PrimeDirect Probe RT-qPCR Mix and primers and probes to final concentrations shown in Table
128 1. Thermal cycling was performed in a ABI7500 Fast instrument (Thermofisher Scientific) with
129 1 cycle of denaturation at 96ºC for 10 sec, 1 cycle of reverse transcription at 60°C for 5 min
130 followed by 45 amplification cycles each consisting of 95°C-5s and 60°C-30s. SARS-CoV-2
131 RT-qPCR with TaqPath™ 1-Step RT-qPCR kit with the optimized approach (specimens heat
132 treated at 65ºC for 10 min) was performed as above except that 8 µl of specimen was used per 20
133 µl reaction.

134 A total of 132 NPS that were previously tested by the standard approach were also tested
135 by the optimized, direct approach and the results were compared. In addition, an external quality
136 assessment (EQA) panel (8 specimens) from Quality Control for Molecular Diagnostics
137 (QCMD) was tested simultaneously with the standard and the direct approach, as well as with a

138 QIAstat-Dx Respiratory 2019-nCoV Panel (Qiagen) and the results were compared with
139 expected results.

140 Limit of detection (LOD) study: A SARS-CoV-2 positive nasopharyngeal specimen (C_T
141 = 23.3) was titered by the optimized approach using synthetic RNA, and serially diluted (up to
142 $5x10^{-7}$ - fold) using a negative specimen. All diluted specimens were pre-treated by heating at
143 65ºC for 10 min and then assessed by SARS-CoV-2 RT-qPCR in replicates of 8. The C_T values
144 obtained were used to calculate limit of detection (LOD) and intra-assay reproducibility of direct
145 RT-qPCR.

146 Statistical analysis: Sensitivity, defined as the number of true positive results divided by
147 the sum of true positive and false negative results; specificity, defined as the number of true
148 negative results divided by the sum of true negative and false positive results; and accuracy
149 (concordance), defined as the sum of true positive and true negative results divided by the total
150 number of test samples, were calculated and expressed as percentages. Ninety-five percent
151 confidence intervals (CI) for sensitivity, specificity and accuracy were calculated by the Clopper-
152 Pearson interval or exact method using an online, diagnostic test evaluation calculator (MedCalc,
153 2018). Correlation between the RT-qPCR CT values between standard approach and optimized
154 direct approach was determined by Pearson's coefficient calculator. The limit of detection with
155 95% endpoint (C_{95}) was determined by Probit regression analysis [11].

156

157 **Results**

158 Using a human coronavirus HKU1 (hCoV-HKU1) positive specimen as a surrogate for
159 SARS-CoV-2, we first assessed whether specimens can be used directly for RT-qPCR after 2-10
160 fold dilution with nuclease free water (NFW), simple heat treatment (100ºC for 5 min) and

161 centrifugation to remove any insoluble material that may be present in the specimen. The pre-
162 treated specimens were then assessed in parallel with extracted specimens by a previously
163 described, laboratory developed RT-qPCR for HCoV-HKU1 (Table S1). A significant loss of
164 sensitivity was observed with a RT-qPCR ΔC_T ranging from 10-14 (Table S2). To determine
165 whether any components of UVT medium (Becton, Dickinson and Company) were inhibitory to
166 RT-qPCR, we collected nasopharyngeal flocked swabs (NPFS) from laboratory volunteers in
167 NFW along with swabs in UTM. We then spiked a SARS-CoV-2 positive specimen to all
168 specimens and assessed them by SARS-CoV-2 RT-qPCR. However, no significant improvement
169 in sensitivity was observed (Table S3).

170 Similar results were observed when two commercial test kits were used for direct RT-
171 qPCR: Arcis Coronavirus RNA extraction research kit comes with lysis reagents that can be used
172 directly in RT-qPCR; and Takara PrimeDirect™ Probe RT-qPCR kit provides a master mix that
173 is compatible with heat-treated specimen extracts. However, in our evaluation both test kits
174 failed to demonstrate an acceptable level of sensitivity (Tables S4 and S5). Our attempts to
175 further optimize the pre-treatment conditions showed modest improvement with a non-ionic
176 detergent, Tween-20, and further improvement with a heating step at 65ºC for 10 min without
177 centrifugation ($\Delta C_T = 5.2$) (Table S6). We then tested this low heat approach with more SARS-
178 CoV-2 positive specimens and using 3 different RT-qPCR master mixes. Interestingly, we found
179 that with TaqPath™ 1-Step RT-qPCR Master Mix, 4/4 positive samples were correctly detected
180 with a ΔC_T range 0.8 – 3.8 (Table 1). On the other hand, two other master mixes gave higher ΔC_T
181 and 1/4 positive results were missed by both. Based on these results, the optimal pre-treatment
182 and reaction conditions for the direct approach were: i) transfer and dilute (4-fold) 10 µl of NPFS

183 specimen in NFW; ii) incubate at 65°C for 10 min; and iii) test 8 µl of heat lysed specimen in a
184 20 µl reaction using TaqPath™ 1-Step RT-qPCR Master Mix.

185 The analytical sensitivity of the direct RT-qPCR assay using specimens prepared in this
186 manner was determined by serially diluting a specimen positive for SARS-CoV-2 with a
187 negative specimen as a diluent. The positive specimen was titered based on the C_T value
188 obtained by the direct approach using a standard curve prepared with SARS-CoV-2 synthetic
189 RNA. The C_T values were linear (R^2 = >0.99) over the range of 10^3 copy/ml to 10^8 copy/ml, the
190 highest concentration used in this analysis (Fig. 1A and 1B). The 95% limit of detection (LOD;
191 C_{95}) of the assay with the direct approach was $6.6X10^3$ copy/ml. The C_T variation between RT-
192 qPCR replicates across different concentration of analytes were <1 with an average coefficient of
193 variation (CV%) of 1.2%.

194 A total of 132 NPFS specimens that were previously tested with standard approach
195 including viral RNA extraction were re-tested with the new direct approach. The direct approach
196 detected all except one positive case with C_T>38. On the other hand, the direct approach detected
197 (C_T>37) SARS-CoV-2 in one specimen that was negative by standard approach. Overall
198 agreement of results between two approaches was >98% (Kappa= 0.939; 95% CI = 0.854 to
199 1.000). The sensitivity and specificity of the new approach compared to the reference method
200 were 95% and 99%, respectively (Table 2). The RT-qPCR C_T values for all specimens that were
201 positive by both methods (n=18) were positively correlated with a Pearson coefficient (R) of
202 0.6971 (p<0.01) (Fig. 2). The rate of PCR inhibition among the specimens that gave negative
203 RT-qPCR results by the direct approach was 8% compared to 9% by the standard approach.
204 Finally, the direct approach accurately detected SARS-CoV-2 RNA in all except one specimen in
205 an external quality assessment (EQA) panel provided by Quality Control for Molecular

206 Diagnostics (QCMD)(Table S7). The specimen that gave discrepant result was reported as
207 'borderline' by QCMD, and SARS-CoV-2 RNA was also undetectable in this specimen by
208 standard approach and by a commercial test, QIAstat-Dx Respiratory 2019-nCoV Panel
209 (Qiagen).
210

211 **Discussion**

212 Success in RT-qPCR testing depends on multiple factors. RNA extraction is preferable to
213 the use of direct specimens because the extraction process concentrates and purifies the RNA
214 targets and excludes PCR inhibitory substances. The use of pre-treated or untreated specimens
215 directly in RT-qPCR is challenging because of the presence of inhibitors and RNA loss due to
216 heating and/or RNases. After many attempts with various pre-treatment agents and conditions,
217 we have determined an optimal pre-treatment protocol complemented with specific RT-qPCR
218 reagents, that generates results equivalent to standard methods that involve RNA extraction.
219 Minimizing RNA loss through the low heat approach, appropriate dilution of inhibitory
220 substances and the higher sensitivity of TaqPath™ 1-Step RT-qPCR Master Mix may have
221 played a combinatory role in achieving equivalency of the direct RT-qPCR compared to a
222 standard approach requiring viral RNA extraction.

223 In summary, our new approach demonstrated high sensitivity and specificity in the
224 detection of SARS-CoV-2 RNA, and the rate of RT-qPCR inhibition was similar to that of a
225 standard approach. By skipping the RNA extraction step, the new approach will also
226 significantly reduce the cost and improve the turn-around time of the assay. Delayed and
227 inadequate laboratory testing can significantly hamper efforts to control the pandemic. Our
228 results will help many labs all over the world who are struggling with a shortage of reagents to

229 continue testing for SARS-CoV-2. Also, because of a significant reduction in cost, the optimized
230 direct approach we described, will be useful to resource-limited countries to expand their
231 capacity for RT-qPCR testing.
232

233 **Acknowledgement**

234 We are grateful for the efforts of all technologists in the Molecular Infectious Disease Laboratory
235 at Sidra Medicine.

236 **References**

237 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et. Al. A Novel Coronavirus from
238 Patients with Pneumonia in China, N Engl J Med 2019;382(8):727-733.
239 2. Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health
240 Organization declares global emergency: A review of the 2019 novel coronavirus
241 (COVID-19). Int J Surg 2020;76:71-76.
242 3. Steffens I. A hundred days into the coronavirus disease (COVID-19) pandemic,
243 Eurosurveillance. https://www.eurosurveillance.org/content/10.2807/1560-
244 7917.ES.2020.25.14.2000550#r8. Accessed 18 April 2020.
245 4. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of
246 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;25(3).
247 5. Ranney ML, Griffeth V, Jha AK. Critical Supply Shortages - The Need for Ventilators
248 and Personal Protective Equipment during the Covid-19 Pandemic. N Engl J Med
249 2020;doi: 10.1056/NEJMp2006141.

250 6. Slabodkin G. FDA chief warns of supply 'pressure' on reagents for coronavirus tests.
251 https://www.medtechdive.com/news/fda-chief-warns-of-supply-pressure-on-reagents-for-
252 coronavirus-tests/573999/. Accessed 18 April 2020.
253 7. Yan Y, Chang L, Wang L. Laboratory testing of SARS-CoV, MERS-CoV, and SARS-
254 CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. Rev Med Virol
255 2020;17:e2106.
256 8. World Health Organization (WHO). Coronavirus disease (COVID-19) Pandemic.
257 Geneva: WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
258 Accessed 18 April 2020.
259 9. Hasan MR, Al Mana H, Young V, Tang P, Thomas E, Tan R, et al. A novel real-time
260 PCR assay panel for detection of common respiratory pathogens in a convenient, strip-
261 tube array format. J Virol Methods 2019;265:42-48.
262 10. Dreier J, Stormer M, Kleesiek K. Use of bacteriophage MS2 as an internal control in viral
263 reverse transcription-PCR assays. J Clin Microbiol 2005;43:4551-7.
264 11. Burd EM. Validation of laboratory-developed molecular assays for infectious diseases.
265 Clin Microbiol Rev 2010;23(3):550-576.
266
267
268
269
270
271

272 Table 1: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens after heating
273 at 65°C for 10 minutes with different RT-qPCR master mixes

Sample No.	SARS-CoV-2 C_T			
	Standard method	Quantifast Pathogen RT-PCR + IC Master Mix	PrimeDirect™ Probe RT-qPCR Mix	TaqPath™ 1-Step RT-qPCR Master Mix
1	21.5	29.4	24.6	22.8
2	34.5	Undetermined	Undetermined	35.3
3	24.5	30.4	28.7	25.5
4	22	29.9	31.4	25.8
5	Undetermined	Undetermined	Undetermined	Undetermined

274

275 NPFS specimens were either subjected to viral RNA extraction by standard method using the
276 NucliSENS easyMAG automated extraction system (bioMerieux), or diluted 4-fold with NFW
277 followed by incubation at 65°C for 5 minutes. All samples were tested for SARS-CoV-2 RNA by
278 standard RT-qPCR using different master mixes in duplicate and mean C_T values were
279 compared.

280

281 Table 2: Performance of optimized direct RT-qPCR approach with reference to standard

282 approach for detection of SARS-CoV-2 RNA

283

Statistic	Value	95% CI
Total number of specimens	132	-
True positive	18	-
True negative	112	-
False positive	1	-
False negative	1	-
Sensitivity	95.0%	74% to 99.8%
Specificity	99.0%	95.2% to 99.9%
Accuracy	98.5%	94.6% to 99.8%

284

285

286

287

288

289

290

291

292 **Figure legends**

293 Figure 1: Linearity of SARS-CoV-2 RT-qPCR by direct approach. A tittered SARS-CoV-2
294 positive nasopharyngeal specimen was serially diluted using a negative specimen, pre-heated at
295 65ºC for 10 min and assessed by SARS-CoV-2 RT-qPCR as described in the Supplemental
296 methods. A) Amplification curves from SARS-CoV-2 RT-qPCR assay on the serially diluted
297 sample. B) RT-qPCR C_T values were plotted against estimated copy number of SARS-CoV-2
298 RNA in each dilution. Each data point represents an average of data obtained from 8 replicates.

299

300 Figure 2: Correlation of RT=qPCR C_T values obtained by direct versus standard approach.

301

302

303

304

305

306

307

308

309

310

Figure 1


A)
Amplification Plot
ΔRn
Cycle
B)
RT-qPCR C_T
R^2 = 0.9948
SARS-CoV-2 RNA copy/ml
100
10000
1000000
100000000

328 Figure 2

329

330

331

332

333

334

335



336

337

338

339

340

341

342

343

344

345 **Supplemental Tables**

346

347 Table S1: Primers and probes used in this study

Assay	Target	Name	Sequence (5′- 3′)	5’-Label	3’-Label	Final concentration (μM)	Source
HCoV-HKU1	Nucleocapsid gene	HCoV-HKU1-F	GATCCTACTAYTCAAGAAGCTATCCCTACT			0.6	(1)
		HCoV-HKU1-R	ACCTTCCTGAGCCTTCAACATAAT			0.3	
		HCoV-HKU1-P	TTTYCGCCTGGTACGATTTTGCCTC	JOE/ZEN	IaBkFQ	0.2	
SARS-CoV-2	E gene	E_Sarbeco_F1	ACAGGTACGTTAATAGTTAATAGCGT			0.4	(2)
		E_Sarbeco_R2	ATATTGCAGCAGTACGCACACA			0.4	
		E_Sarbeco_P1	ACACTAGCCATCCTTACTGCGCTTCG	FAM/ZEN	IaBkFQ	0.2	
	Internal control	MS2-TM3-F	GGCTGCTCGCGGATACCC			0.2	(3)
		MS2-TM3-R	TGAGGGAATGTGGGAACCG			0.2	
		MS2-TM2JOE	ACCTCGGGTTTCCGTCTTGCTCGT	JOE/ZEN	IaBkFQ	0.1	

348

349

350

351

352

353

354

355

356

357

358

359 Table S2: Direct RT-qPCR on a nasopharyngeal specimen positive for human coronavirus HKU1 after
360 heat treatment at 100ºC for 5 minutes

361

Sample Name	Sample dilution	Sample processing	HKU1 CoV C_T	
			Quantifast Pathogen RT-PCR + IC Master Mix	TaqPath™ 1-Step RT-qPCR Master Mix
1167-H0	Undiluted	easyMAG extraction	24.6	23.8
1167-H1	Undiluted	Heat treatment	36.4	36.6
1167-H2	2 fold dilution	Heat treatment	34.5	35.7
1167-H3	4 fold dilution	Heat treatment	34.7	35.6
1167-H4	10 fold dilution	Heat treatment	34.1	33.2
1167-H5	Undiluted	Freeze thaw; heat treatment	38.1	36.1

362

363 NPFS specimens were either i) subjected to viral RNA extraction by standard method using a NucliSENS
364 easyMAG automated extraction system (Biomerieux), or ii) serially diluted with nuclease free water
365 (NFW) followed by incubation at 100ºC for 5 minutes, or iii) freeze thawed once prior to heat treatment.
366 All heat-treated samples were centrifuged at 13,000 rpm for 5 minutes at 4ºC and supernatants were
367 collected. All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR in duplicate and mean
368 C_T values were compared.

369

370

371

372

373

374

375

376

377 Table S3: Direct RT-qPCR on simulated, dry NPFS using a spiked specimen positive for SARS-CoV-2

Sample No.	SARS-CoV-2 C_T	
	Standard method	Direct PCR on dry NPFS
1	20.8	32.4
2	20.5	25.8
3	20.8	32.4
4	25.7	31.6
5	25.8	33.8
6	25.6	34.5

378

379 Specimens were collected from laboratory members who volunteered to provide specimens. NPFS
380 specimens were either i) collected in VTM or ii) collected in sterile empty tubes as dry swabs and later
381 resuspended in 1 ml of NFW. Five µl of a patient specimen positive for SARS-CoV-2 RNA (C_T = 22)
382 were spiked into 0.2 ml of specimens collected in VTM of NFW. VTM specimens were extracted by
383 standard method using a NucliSENS easyMag automated extraction system (bioMerieux). Specimens
384 collected in NFW were incubated at 100ºC for 5 minutes and centrifuged at 13,000 rpm for 5 minutes at
385 4ºC and supernatants were collected. All samples were tested for SARS-CoV-2 RNA by standard RT-
386 qPCR using Quantifast Pathogen RT-PCR + IC Master Mix in duplicate and mean C_T values were
387 compared.

388

389

390

391

392

393

394

395

396

397

398

399 Table S4: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens processed using
400 Arcis Pathogen Kit

401

Sample No.	SARS-CoV-2 C_T		
	Standard method	Arcis kit with heating	Arcis kit - no heating
1	Undetermined	Undetermined	Undetermined
2	Undetermined	Undetermined	Undetermined
3	Undetermined	Undetermined	Undetermined
4	25.0	34.9	33.5
5	21.0	32.9	Undetermined
6	23.0	28.4	32.3

402

403 NPFS specimens were processed according to manufacturer's protocol (Arcis Biotechnology Ltd.). All
404 samples were tested for SARS-CoV-2 RNA by standard RT-qPCR in duplicate and mean C_T values were
405 compared.

406

407

408

409

410

411

412

413

414

415

416

417

418 Table S5: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens processed using
419 Takara

420

Sample No.	SARS-CoV-2 C_T	
	Standard method	Takara PrimeDirect protocol
1	21.5	29.78692245
2	34.5	Undetermined
3	24.5	Undetermined
4	33.7	Undetermined
5	Undetermined	Undetermined

421

422 NPFS specimens were processed according to manufacturer's protocol (PrimeDirect™ Probe RT-qPCR
423 Mix, Takara Bio Inc.). All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR in duplicate
424 and mean C_T values were compared.

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439 Table S6: Direct RT-qPCR on SARS-CoV-2 positive and negative NPFS specimens with or without
440 heating at 65ºC for 5 minutes or after lysis using a non-ionic detergent

441

Sample No.	SARS-CoV-2 C_T			
	Standard method	No treatment	Heat treatment	Lysis with 0.2% Tween-20
1	21.5	30.6	26.7	28.4
2	34.5	Undetermined	Undetermined	Undetermined
3	Undetermined	Undetermined	Undetermined	Undetermined
4	Undetermined	Undetermined	Undetermined	Undetermined
5	Undetermined	Undetermined	Undetermined	Undetermined

442

443 NPFS specimens were either i) subjected to viral RNA extraction by standard method using a NucliSENS
444 easyMAG automated extraction system (bioMerieux), or ii) diluted 4-fold with nuclease free water
445 (NFW) iii) diluted 4-fold with nuclease free water (NFW) followed by incubation at 65ºC for 5 minutes
446 or iv) diluted 4-fold with Tween-20 to final concentration of 0.2% followed by incubation at room
447 temperature for 10 min. All samples were tested for SARS-CoV-2 RNA by standard RT-qPCR using
448 Quantifast Pathogen RT-PCR + IC Master Mix.

449

450

451

452

453

454

455

456

457

458

459

460

461 Table S7: Direct RT-qPCR on QCMD EQA specimens

462

		SARS-CoV-2 C_T		
Sample No.	QCMD result	Standard approach	QIAstat	Direct approach
Sample 1	Positive	33.4	34	35.5
Sample 2	Negative	undetermined	undetermined	Undetermined
Sample 3	Positive	35.2	35.4	37.1
Sample 4	Negative	undetermined	undetermined	Undetermined
Sample 5	Negative	undetermined	undetermined	Undetermined
Sample 6	Positive	34.2	36.7	35.1
Sample 7	Positive	29.4	31.5	31.7
Sample 8	Borderline	undetermined	undetermined	Undetermined

463

464 QCMD EQA specimens were simultaneously tested by standard and direct approach and by QIAstat-Dx
465 Respiratory 2019-nCoV Panel (Qiagen)

466

467

468

469

470

471

472

473

474